Recent Company News

• 07:25 AM ET Apr 30, 2026
  

  RedHill's RHB-204 demonstrates comparable MAP killing efficacy to RHB-104 ($1.04, 0.00)

• 07:00 AM ET Apr 30, 2026
  

  RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

• 08:04 AM ET Apr 27, 2026
  

  RedHill Biopharma reports FY net income from cont ops ($8.1M) vs year-ago $0.4M ($1.03, 0.00)

• 08:01 AM ET Apr 27, 2026
  

  RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

• 08:08 AM ET Apr 22, 2026
  

  RedHill Biopharma announces presentation of new preclinical data for opaganib at AACR 2026 ($0.80, 0.00)

• 08:00 AM ET Apr 22, 2026
  

  RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

• 07:15 AM ET Feb 25, 2026
  

  RedHill Biopharma announces full sales and operational launch of Talicia ($0.99, 0.00)